Oligodeoxyribonucleotides의 합성을 위한 유기염기의 보호기 도입

노봉오,조재흥,신대현 조선대학교 기초과학연구소 1990 自然科學硏究 Vol.13 No.1

In this study the starting materials, 2'-deoxyriboadenosine and 2'-deoxyribocytidine, were protected selectively as the tritylation of the 5'-hydroxyl group and the N-acylation of the amino group with 4,4'-dimethoxytrityl chloride and benzoyl chloride, in a oneflask procedure. Protection of the amino group and the 5'-hydroxyl group in 2'-deoxyguanosine can be performed directly by isobutyric anhydride and 4,4'-dimenthoxytrityl chloride pyridine to obtain 2-N-isobutyryl-5'-O-dimethoxytrityl-2'-deoxyguanosine in a one-flask procedure. The protected deoxyribonucleotides have been crharacterized on UV, IR and ^1H-NMR spectroscopy.

농부가 아닌 환자에서 발생한 긴털가루진드기(Tyrophagus Putrescentiae)에 의한 기관지천식 1례

최대로,김형수,고창옥,김희선,윤호성,박용범,김상훈,이재영 대한천식 및 알레르기학회 2004 천식 및 알레르기 Vol.24 No.1

Storage mites are believed one of the most important allergens in farmers and rural regions. Tyrophagus putrescenitiae, belonging to storage mites, is found not only within storehouses but also in the house dust, and the third most common mites following Dematophagoides farinae and Dermatophagoides pteronyssnus in house dust in Korea. The sensitization rate to Trophagus putrescentiae was reported as high as that of house dust mite in patients visiting the allergy clinic in large cities in Korea. We experienced a 69-year-old man who had suffered from dyspnea, wheezing, and coughing for 10 years. He retired from the teaching profession, and had lived in a large city. Deajeon. The skin prick test showed a positive reaction to Tyrophagus putrescentiae and negative reactions to house dust mites. The bronchial challenge test with Tyrophagus putrescentiae showed late asthmatic reaction. We confirmed a Tyrophagus putrescentiae induced asthma in non occupational setting. (J Asthma Allergy Clin Immunol 24 : 141-5, 2004)

수유방법 및 기간이 아동의 타액내 환원효소활성검사성적과 유치우식경험도에 끼친 영향

배상만,노동주,김대업,이광희 大韓小兒齒科學會 1996 大韓小兒齒科學會誌 Vol.23 No.3

The purpose of this study was to investigate the effects of the lactation of human or bovine milk and the method of using nursing bottles on the salivary invertase test scores and deciduous caries experience of children. 328 preschool children (boys 178, girls 150) in Iksan city were selected for this study. The parents of the children were asked to answer the questionnaire about the lactation of human or bovine milk and the time of using nursing bottles. The data were obtained from the salvary invertase activity score,(Resazurin Disc Test) deciduous caries experience and the questionnaire. The result were as follows. The invertase activity and caries experience of the human milk higher than that of the bovine milk group(p<0.05). There were significant positive relationships between the lactation period and the invertase activity and between the lactation period and the caries experience(p<0.05). Caries experience had a tendency to increase as the time of using nursing bottles increase(p>0.05).

방사선 조사에 의한 흰주 난포의 퇴축과 난포세포의 방사선 감수성

김수일,한승로,조근자,허대영,이영호,조문준,김무강,김원식 충남대학교 의과대학 의학연구소 2002 충남의대잡지 Vol.29 No.1

The aim of this study were to investigate radiation-induced atresia and radiation susceptibility in the rat ovary morphologically. Female rats (Sprague Dawley strain) of 4 weeks old were irradiated with dose of 4 Gy and 8 Gy, and sacrificed at hour 6, 12, and 24 after radiation. The H & E stain, the TUNEL method (ApopTag kit) and transmission electron microscopy (TEM) were used. In light microscopic observation, the number of atresia of ovarian follicles were increased significantly at 6h after irradiation (p<0.01). There was no significant difference between 4 Gy and 8 Gy irradiated groups. In TEM observation, granulosa cells in radio-sensitive follicles were characterized by several structural features including condensation of nuclear chromatin granules, nuclear fragmentation and apoptotic body formation. An apoptotic cell is observed to have been phagocytosed by a normal granulosa cell. Granulosa cells in radio-resistant follicles were characterized by several structural features including nuclear indentation, partial condensation of chromatin granules, mitochondrial swelling, dilatation of RER cisterns, accumulation of dense irregular masses, accumulation of lipid droplets, and increased lysosomal bodies. Number of gap junctions between granulosa cells were decreased, and intercellular space were widen than that of control animals. These findings were prominent at 6h after irradiation and were diminished at 12h and 24h after irradiation. With these results, it was concluded that radiation-induced follicular cell apoptosis and ovarian follicular atresia in rat ovary increased considerably at 6h after irradiation. Further studies are needed to reveal the more extensive differences between radiosensitive and radioresistant follicular granulosa cells.

Am-Be 선원을 통한 중성자의 전단면적 측정

민영기,오선영,노태익,박상태,이대원,이삼열 東亞大學校 1996 東亞論叢 Vol.33 No.-

Total cross sections was measured for 6.45MeV∼8.96MeV (average 7.7MeV) neutron on ??, ??, ?? absorber using ?? fast neutron source. The 2" ø×2" NE-213 organic liquid scitillation detector was used as a spectrometer of neutrons and gamma-rays. The zero crossing time analysis method was introduced in order to obtain the pulse heigh spectrum of neutrons and n-γ pulse-shape spectrum was investigated. The ratio of neutron peak for a Vally was 1:20. The total cross section resulting from the experiment enabled us to suppose a optical model as a neutron model, obtain the radius of a nuclei.

장상피화생과 Helicobactor pylori와의 상관 관계에 관한 연구

이복희,김대수,이현숙,진영주,윤세진,송형근,성노현,정현용,이동호 충남대학교 의과대학 지역사회의학연구소 1994 충남의대잡지 Vol.21 No.2

In 1965 Lauren divided advanced gastric carcinoma into two main types-namely, "intestinal" and "diffuse" type carcinoma, which differ not only morphologically but also in their clinical and epidemiological characteristics. Moreover, a different histogenetic process has been postulated by many authors that intestinal type gastric carcinoma might arise from areas with intestinal metaplasia. Since Warren and Marshall reported the presence of Helicobacter pylori in the stomach in 1983, strong evidence has been obtained that there is a close relationship between Helicobacter pylori and chronic gastritis, atrophic gastritis, intestinal metaplasia, and intestinal type gastric carcinoma. To study the relationship between intestinal metaplasia and Helicobacter pylori infection, we performed gastroscopic biopsies and CLO tests taken from patients with epigastric pain. Only 87 patients with macroscopically suspected antral gastritis were included. The prevalence of intestinal metaplasia in gastric antral biopsies increased from 33.3% in the age group<30 years to 63.6% in the age group 60 years. When all patients were divided into two age groups-namely, (i)<50 years(n=41) and (ii)≥ 50 years(n-=46), intestinal metaplasia was found significantly more often in patients ≥ 50 years. ((i) 39.2%, (ii) 54.3%, p<0.0001). The prevalence of Helicobacter pylori in gastric antral biopsies decreased from 66.7% in the age group<30 years to 62.5%, in the age group in the age group 50 to 59 years. When all patients were divided into the same two age groups-namely(i)<50 years and (ii)≥50 years, the prevalence of Helicobacter pylori did not differ between two groups in a statistically significant way. The mean age of intestinal metaplasia positive patients who were also Helicobacter pylori positive was 48±11.0(mean±S.D.)years, whereas the mean age of intestinal metaplasia positive patients who were Helicobacter pylori negative was 52±9.7(mean±S.D.)years. In conclusion. although our data do not prove a causal relationship between Helicobacter pylori infection and the histogenesis of intestinal metaplasia, we suggest that Helicobacter pylori plays an important role in the development of intestinal metaplasia in the gastric mucosa. Whether Helicobacter pylori has to be present at all times during this process or is only necessary as a 'trigger', needs further research.

만성 B형 간질환에서 라미부딘 초치료 후의 재발 양상과 재치료 효과

박종호,박능화,신정우,방성조,김대현,주광로,김도하 대한간학회 2003 Clinical and Molecular Hepatology(대한간학회지) Vol.9 No.3

목적: 만성 B형 간염 환자에 라미부딘은 효과적이지만 서양의 보고와 달리 국내에서는 치료 종료 후 재발률이 높은 것으로 알려져 있다. 그러나 라미부딘 치료 종료 후의 재발 양상이나 재발군에서 라미부딘의 재투여에 대한 치료 효과는 알려져 있지 않다. 본 연구에서는 치료 종료 후 재발 양상과 재발군에서 라미부딘 재치료 효과를 알아보고자 하였다. 대상과 방법: 만성 B형 간질환으로 진단받고 라미부딘을 치료받은 환자 중 치료에 반응한 후 투약을 중지한 121명 중에서 재발한 42명(만성 간염 36예, 대상성 간경변 6예)을 대상으로 하였다. 라미부딘을 1일 100 ㎎씩 6개월(평균 16개월, 범위: 6-35개월) 이상 투여하였다. 평균 연령은 39.7세였고 남녀 비는 35:7이었다. 재치료 전 혈청 ALT 평균치는 437 IU/L, AST 평균치는 227 IU/L, HBV DNA 평균치는 519 pg/mL였다. 치료반응군에서는 치료 반응이 있은 뒤 추가로 라미부딘을 투여하여 적어도 2개월 이상 반응이 유지된 후 투약을 중지하고 재발 유무를 추적 관찰하였다. 겨로가: HBeAg이 혈청전환된 192예 중 121예(63%)에서 투여를 중단하였으며 평균 추적 기간은 8.9개월(범위: 1-40개월)이었다. 66명(54.5%)에서 재발하였으며 평균 재발 시기는 5.7개월(범위: 1-33개월)이었다. 50예(75.8%)에서는 HBeAg 양성 만성 간질환으로, 16예(24.2%)는 HBeAg 음성 만성 간질환으로 재발하였다. 누적 재발률은 1개월 후 6%, 3개월 후 27%, 6개월 후 47%, 12개월 후 60%, 18개월 후 64%, 24개월 후 66%이었다. 재발과 관련된 예측 인자로는 연령, 치료 전 정량적 HBeAg치, HBV DNA치가 의미 있는 인자였으며 30세 이하의 25명 중 5명만이 재발하였다. 재발한 66명 중에서 혈청 ALT치가 지속으로 상승된 42예(64%)에서 라미부딘을 재투여 하였다. 31예(73.8%)에서 반응이 있었으며 누적 치료 반응률은 6개월 62%, 9개월 69%, 12개월 72%였다. Breakthrough는 6예(14.3%)에서 일어났으며 전부 HBeAg 양성 만성 간질환 환자였다. 적어도 24개월 이상 치료반응이 유지된 21예에서 투여를 중지하였으며 이 중 11예(52.4%)에서 재발하였다. 재치료한 HBeAg 양성군과 음성군 간에 치료반응률, breakthrough률, 재발률 등도 유의한 차이는 없었다. 라미부딘 재투여의 치료 반응 예측 인자로는 라미부딘 투여기간(p=0.003)이 유의하였으며 breakthrough와 관련된 인자는 없었다. 결론: 라미부딘 초치료 후 재발률은 높았으며 재발 형태는 HBeAg 양성뿐만 아니라 HBeAg 음성 만성 B형 간질환의 형태로도 나타났다. 라미부딘 재치료는 초치료보다는 높은 치료 반응률을 보였으나 breakthrough률과 재발률은 초치료와 비슷하였다. Background/Aims: The post-treatment relapse patterns and efficacy of lamivudine re-treatment for relapsed patients have not been clarified. The aims of this study were to evaluate the relapse patterns after discontinuing therapy and the effects of lamivudine re-treatment for relapsed patients after HBeAg seroconversion. Methods: Therapy was discontinued after HBeAg seroconversion in 121 patients. Sixty-six patients were relapsed and included in this study. The duration of lamivudine re-treatment therapy was from 6-35 (mean:16) months. Post-retreatment monitoring continued for 1-40 (mean:8.9) months. Results: Among the relapsed 66 patients, 50 (75.8%) had HBeAg reappearance while 16 (24.2%) remained HBeAg negative and anti-HBe positive. The cumulative relapse rates at 3, 6, 12 and 24 months were 27%, 47%, 60% and 66% respectively. Forty-two relapsers received lamivudine re-treatment. Among them, 33 were HBeAg positive and 9 were HBeAg negative and anti-HBe positive, Response was achieved in 31 of the 42 patients (73.8%). The cumulative response rates at 6, 9 and 12 months were 62%, 69% and 72%, respectively. Six patients (14.3%) developed viral breakthrough. All patients were HBeAg positive chronic hepatitis B. The duration of lamivudine re-treatment was the only predictable factor for response of lamivudine re-treatment. Therapy was discontinued after response in 21 patients. Eleven patients were relapsed, including 6 who were HBeAg positive and 5 who were HBeAg negative. Predictive factors for post-retreatment relapse were age and the duration of additional lamivudine therapy after response. Conclusions: The response rate of lamivudine re-treatment was significantly higher than in initial lamivudine treatments. The breakthrough and relapse rates, however, were similar in both initial and retreated lamivudine therapy.(Korean J Hepatol 2003;9:188-197)

HBeAg 음성 만성 B형 간질환에서 Lamivudine의 치료 효과

정인두,박능화,김병철,박지현,서광원,김대현,주광로,김도하 대한간학회 2003 Clinical and Molecular Hepatology(대한간학회지) Vol.9 No.2

목적: HBeAg 음성 만성 B형 간질환 환자에서 라미부딘 치료 효과, 내성 발생률, 치료 종료 후 재발률 및 각각의 예측 인자를 알아보고자 하였다. 대상과방법: HBeAg 음성, anti-HBe 양성이나 HBV DNA가 양성인 HBeAg 음성 만성 B형 간질환으로 진단 받은 환자 중에서 혈청 ALT치가 상승되어 있는 59명을 대상으로 라미부딘을 1일 100mg씩 6개월(평균 14개월)이상 투여하였다. 평균 연령은 42.1세였고 남녀 비는 52:7이였다. 치료 전 혈청 ALT평균치는 368 IU/L, HBV DNA평균치는 494 pg/mL였다. 치료 전, 치료 개시 후 및 종료후 1-2개월 간격으로 간기능 검사, HBeAg, anti-HBe, HBV DNA를 측정하였다. 치료 반응군은 반응이 일어난 시점을 기준으로 1-2개월 간격으로 2번 이상 반응이 유지되는 것을 확인한 후 투약을 중지하고 재발 유무를 추적 관찰하였다. 결과: 라미부딘 투여 후 50명 중 56명(94.9%)에서 혈청 HBV DNA가 음전되었으며 누적 음전율은 1개월후 27%, 2개월 후 71%, 3개월 후 90%, 5개월 후 95%였다. 혈청 ALT치는 52명(88.2%)에서 정상으로 회복되었으며 대부분 6개월 내에 이루어졌다. 혈청 ALT치의 누적 정상화율은 2개월 후 30%, 3개월 후 47%, 6개월 후 78%, 10개월 후 86%였다. 혈청 HBV DNA가 음전되고 혈청 ALT치가 정상으로 유지된 치료 반응은 52예(88.1%)에서 일어났으며, 누적 치료반응률은 2개월 후 10%, 4개월 후 49%, 6개월 후 66%, 10개월 후 80%, 18개월 후 88%였다. 라미부딘 총 투여 기간이 유일한 치료 반응 예측 인자였다(p=0.000). 변이형의 출현은 5예(8.5%)에서 일어났고 누적 발생률은 10개월 후 8%, 16개월 후 13%였다. Breakthrough발생 예측인자와 관련된 유의한 인자는 없었다. 치료 반응군중 투여 중지한 34명 중 17명(50%)에서 재발하였으며(평균추적기간: 6개월, 범위: 1-22개월) 대부분 투여중지 6개월 내에 재발하였다. 누적 재발률은 3개월 후 24%, 6개월 후 47%, 10개월 후 66%였다. 재발과 관련된 예측 인자는 치료 반응후 추가적인 라미부딘 누여만이 유의한 인자였다(p=0.019). 특히 12개월 이상 유지한 7명 모두에서 재발하지 않았다. 결론: 라미부딘은 HBeAg 음성 만성 B형 간질환에서 높은 치료효과와 낮은 breakthrough를 보였으며 라미부딘 투여 기간만이 유일한 치료 반응 예측 인자이었다. 그러나 치료 종료 후 많은 예에서 재발하였으며 치료 반응 후 추가적인 라미부딘 투여 기간만이 유일한 재발 예측 인자였으며 재발을 막기 위해서는 장기간의 추가적인 라미부딘 투여가 필요할 것으로 사료된다. Background/Aims: Lamivudine therapy is effective in inhibiting HBV replications in patients with HBeAg-negative chronic liver disease. However, the sustained response rate appears to be particularly poor, because the vast majority of patients relapse soon after cessation of therapy. The aim of this study was to evaluate the efficacy of lamivudine, the breakthrough rate, and the relapse rate of discontinuing therapy after response in patients with HBeAg-negative chronic liver disease. Methods: Fifty-nine patients with HBeAg-negative chronic liver disease who have received lamivudine for at least 6 months, were studied. The mean duration of treatment was 14 months. Complete response was defined as undetectable serum HBV DNA by bDNA and normalization of ALT levels. Once HBV DNA disappearance and ALT normalization were observed, lamivudine therapy was continued for at least two additional months. The mean follow-up after cessation of treatment was 6 (1-22) months. Results: Fifty-six patients were undetectable HBV DNA. The cumulative HBV DNA loss rates at 3 months and 5 months were 90% and 95%, respectively. The ALT normalization was observed in 52 patients. The cumulative ALT normalization rates at 6 months and 10 months were 78% and 86%, respectively. The complete response was observed in 52 patients. The cumulative rates of complete response at 10 months and 18 months were 80% and 88%, respectively. A predictive factor for complete response was only the duration of lamivudine treatment. Virological breakthrough was observed in 5 (8.5%). Thirty-four patients stopped taking lamivudine after 7.7 (2-15) months of the additional therapy. Seventeen of those patients (50%) experienced relapse. The cumulative relapse rates at 3 months, 6 months and 10 months were 24%, 47% and 66%, respectively. The only predictive factor for relapse was the duration of additional lamivudine treatment after response. Conclusions: Lamivudine was an effective treatment of HBeAg negative chronic liver disease. Relapse, however, was usually observed after cessation of lamivudine. Our results showed that long-term lamivudine therapy is required in order to decrease the high relapse rates in patients with HBeAg-negative chronic liver disease.

만성 B형 간질환에서 라미부딘 내성의 임상경과 및 예측인자

박능화,신정우,박종호,방성조,김대현,주광로,김도하 대한간학회 2003 Clinical and Molecular Hepatology(대한간학회지) Vol.9 No.4

목적: 라미부딘의 투여기간이 길수록 약제내성 변이형 바이러스의 발생률이 증가하게 된다. 변이형의 장기적인 임상적 의의는 논란이 많다. 본 연구는 B형 간염 바이러스에 의한 만성 간질환자에서 변이형이 생긴 뒤의 임상적 경과와 변이형의 발생을 예측할 수 있는 인자를 알아보고자 하였다. 대상과 방법: 만성 B형 간 질환자로 진단 받은 환자 중 라미부딘 치료도중에 viral breakthrough가 생긴 124명을 대상으로 하였다. 평균 연령은 40세였고 남녀 비는 105:19였다. 치료 전 혈청 평균 ALT치는 223 IU/L, 혈청 평균 AST치는 127 IU/L, 혈청 평균 HBV DNA치 1216 pg/mL, 치료 전 정량적 평균 HBeAg치 259이였다. 라미부딘은 1일 100 ㎎씩 breakthrough가 발생한 124명에게 계속 투여하였으며 1, 2개월 간격으로 간기능 검사, HBeAg, anti HBe, HBV DNA 검사를 시행하였다. 라미부딘 총 평균투여 기간은 30.5개월(범위: 10-59개월)이었으며 breakthrough 후 라미부딘 평균 투여기간은 12.5개월(범위: 1-42개월)이였다. 결과: 라미부딘 투여 환자 519명 중 124명에서 viral breakthrough가 5-41개월 사이에 발생하였으며 누적발생률은 12개월 후 8%, 18개월 후 24%, 24개월 후 36%, 36개월 후 52%였다. Viral breakthrough가 생긴 6개월 이내에 120명에서 혈청 ALT치가 상승하였으나 4명에서는 계속 정상으로 유지되었다. 혈청 ALT치는 대부분 상승한 뒤 5개월 내에 최고치에 도달하였으나 6명에서는 12개월 이후에 최고치에 도달하기도 하였다. ALT치는 72명(65%)에서 치료 전 값 이상으로 상승하였으며, 67명(56%)에서 정상치의 5배 이상, 29예(24%)에서 10배 이상 상승하였다. Breakthrough후에 라미부딘 계속투여로 혈청 ALT치가 정상으로 유지된 경우는 22예(18%)에 불과하였으며 98예는 치료전보다 높게 유지되었고 16예에서는 지속적으로 상승하였다. Breakthrough후의 혈청 ALT치 및 AST치가 치료 전보다 의미 있게 상승하였으나 혈청 HBV DNA치는 차이가 없었다. Breakthrough후에 10명에서 HBeAg의 음전이 있었으나 5예에서는 음전 후에 HBV DNA가 재양전되고 혈청 ALT치가 상승되는 HBeAg 음성 만성 간염형태로 나타났다. Breakthrough와 관련된 예측자로 치료 중 정량적 HBeAg의 변화양상만이 유일하게 의미가 있어 감소 후 증가군 82.5%에서,. 지속적 유지군 23.7%에서 Breakthrough가 발생하였으나 지속적 감소군에서는 단지 3.5%만이 발생하였다. 또한 감소 후 증가군에서 정량적 HBeAg치의 감소 후 재상승시점은 약물투여후 평균 9개월로 HBV DNA가 재양전되는 평균시점인 16개월보다 의미 있게 짧았다. Breakthrough후에 투약을 중지한 예는 40예(33%)였다. 이 중 11예에서 중단전보다 혈청 ALT치가 상승되었으며 8개월 내에 전예에서 발생하였다. 중단시 혈청 ALT치가 치료 전 수치보다 높은 경우에서 중단한 26예 중 25명은 중단 후에 혈청 ALT치가 중단 시보다 낮았지만 치료 전 수치보다 낮은 경우에서 중단한 14명 중 10예에서 중단 후에 중단 시보다 더 높아졌다. 결론: 만성 B형 간염환자에서 라미부딘 투여 중에 발생한 HBeAg후의 임상양상은 상당수에서 급성악화를 보였다. Breakthrough를 예측할 수 있는 인자로는 치료 중 정량적 HBeAg치의 변화양상만이 유일한 인자였으며 HBeAg치가 지속적 감소 후에 다시 증가하는 양상을 보인 경우에는 HBV DNA의 재양전보다 더 빨리 Breakthrough을 예측할 수 있었다. Background/Aims: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course in lamivudine after breakthrough, and to identify predictive factors of breakthrough. Methods: 124 patients with chronic hepatitis B infection, who represented viral breakthrough during lamivudine therapy, were included. The mean duration of lamivudine therapy and additional lamivudine therapy after breakthrough was 30.5 months and 12.5 months, respectively. Results: The cumulative breakthrough rates at 12, 18, 24 and 36 months were 8, 24, 36 and 52%, respectively. After viral breakthrough, only 4 patients maintained normal ALT levels. 120 patients showed ALT elevation. The number of patients with ALT levels greater than 5 times, and greater than 10 times, the upper normal limit were 67(56%) and 29 (24%), respectively. While still on lamivudine therapy after breakthrough, 98 patients presented ALT elevation. Only 22 had normalized ALT levels. Hepatic decompensation developed in 2 patients. HBeAg seroconversion after breakthrough occurred in 10 patients. The changing pattern of quantitative HBeAg levels during lamivudine therapy was the only predictive factor associated with viral breakthrough. The mean time of turning points in decrescendo-crescendo patterns of HBeAg levels during lamivudine therapy was earlier than viral breakthrough (9 months vs. 17 months). Conclusions: These results suggested that deterioration of hepatic function can usually be observed after breakthrough. The serial monitoring of serum quantitative HBeAg levels may allow an early recognition of viral breakthrough.(Korean J Hepatol 2003;9:293-303)

[Poster] Recurrence pattern after curative LAR for rectal cancer : Open vs. Laparoscopic vs Robotic

Dae Ro Lim,Hyuk Hur,Byung Soh Min,Seung Hyuk Baik,Kang Young Lee,Nam Kyu Kim 대한외과학회 2011 대한외과학회 학술대회 초록집 Vol.2011 No.11